Product Information
AURYXIA 210 MG TABLET is a brand product labeled by Akebia Therapeutics, Inc., priced at $7.4809 per EA under NDC 59922063101. Its NADAC has been published 572 times since Oct 21, 2015.
FDA first approved this application on Sep 5, 2014. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
210 mg/1
Manufacturer
Akebia Therapeutics, Inc.NDC
59922063101
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
2/18/2026
Active Ingredients
TETRAFERRIC TRICITRATE DECAHYDRATEApproval Type
New Drug (NDA)
FDA Application
NDA205874FDA Approved
9/5/2014
TE Code
AB
On Market Since
9/17/2014
Pharmacological Classes
Price Statistics
The NADAC for AURYXIA 210 MG TABLET has been published 572 times since Oct 21, 2015, and over the history we have for it it has risen 69.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $7.4809 per EA |
|---|---|
| All-time high | $7.4809 (Sep 30, 2026) |
| All-time low | $4.4266 (Oct 21, 2015) |
| 52-week high | $7.4809 |
| 52-week low | $7.4174 |
| Median price | $6.1307 |
| Average price | $6.1237 |
| Largest weekly change | +9.9% (Jul 6, 2016) |
| Weeks tracked | 572 |
| Tracking since | Oct 21, 2015 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the ferric citrate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Akebia Therapeutics, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
ferric citrate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Parenteral Iron Replacement class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of AURYXIA 210 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for AURYXIA 210 MG TABLET, manufactured by Akebia Therapeutics, Inc., is $7.4809 per EA (NDC 59922063101), effective Sep 30, 2026.
How has the price of AURYXIA 210 MG TABLET changed over time?
Over the history we have for it, the NADAC for AURYXIA 210 MG TABLET has risen 69.0%. It has been tracked across 572 weekly CMS publications since Oct 21, 2015.
What are the highest and lowest recorded NADAC prices for AURYXIA 210 MG TABLET?
Since Oct 21, 2015, the NADAC for AURYXIA 210 MG TABLET has ranged from a low of $4.4266 (Oct 21, 2015) to a high of $7.4809 (Sep 30, 2026), with a median of $6.1307 per EA.
Are there cheaper alternatives to AURYXIA 210 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of AURYXIA 210 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures AURYXIA 210 MG TABLET?
AURYXIA 210 MG TABLET (NDC 59922063101) is labeled by Akebia Therapeutics, Inc., and CMS classifies it as a brand product.